JP2008105983A - Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink - Google Patents
Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink Download PDFInfo
- Publication number
- JP2008105983A JP2008105983A JP2006289307A JP2006289307A JP2008105983A JP 2008105983 A JP2008105983 A JP 2008105983A JP 2006289307 A JP2006289307 A JP 2006289307A JP 2006289307 A JP2006289307 A JP 2006289307A JP 2008105983 A JP2008105983 A JP 2008105983A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- fibroblast proliferation
- extracts
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
Abstract
Description
本発明は、皮膚の弾力、張り、潤いに重要な役割を担う線維芽細胞の増殖促進剤に関する。更には、該線維芽細胞増殖促進剤を含有する皮膚外用剤、浴用剤及び飲食物に関する。 The present invention relates to a fibroblast growth promoter that plays an important role in skin elasticity, tension and moisture. Furthermore, it is related with the skin external preparation, the bath preparation, and food and drink containing this fibroblast growth promoter.
近年、高齢化社会や女性の社会進出に伴い、美容に対する意識が向上している。しかし、皮膚の機能は年齢とともに低下し、加齢により弾力や張りを失い、シワが生じてくる。この原因として、皮膚中に存在する線維芽細胞が産生するコラーゲンとヒアルロン酸の量の低下が挙げられる。 In recent years, the awareness of beauty has improved with the aging of society and the advancement of women into society. However, the function of the skin decreases with age, and with age, it loses its elasticity and tension, and wrinkles occur. This may be due to a decrease in the amount of collagen and hyaluronic acid produced by fibroblasts present in the skin.
皮膚は皮下組織、真皮、表皮の三層から成っていて、皮膚の弾力など皮膚機能に最も影響を与えるのが真皮であり、この真皮にはコラーゲンとヒアルロン酸が多く含まれている。これらコラーゲンやヒアルロン酸は、真皮中に存在する線維芽細胞が産生することが知られており、皮膚の弾力性の保持に重要な役割を担っている。 The skin consists of three layers of the subcutaneous tissue, the dermis, and the epidermis. The dermis has the most influence on the skin function such as the elasticity of the skin, and the dermis is rich in collagen and hyaluronic acid. These collagen and hyaluronic acid are known to be produced by fibroblasts present in the dermis, and play an important role in maintaining the elasticity of the skin.
また線維芽細胞は、真皮以外にも、全身の結合組織に散在しており、各組織や器官の結合に重要な役割を果たすことが知られていることから、線維芽細胞増殖を調節することによる創傷の治療、線維腫の予防、老化の予防への応用が期待されている。 In addition to dermis, fibroblasts are scattered throughout the connective tissues throughout the body and are known to play an important role in the connection of tissues and organs. It is expected to be applied to the treatment of wounds, prevention of fibroma, and prevention of aging.
皮膚の弾力性保持、すなわち皮膚の老化を防止するために、今までに様々な手段が提案されている。例えば特許文献1には、「ゲンクワニンを有効成分として含有する、皮膚外用剤」が記載されている。特許文献1記載の皮膚外用剤に含有されるゲンクワニンは、線維芽細胞におけるコラーゲン、及びヒアルロン酸産生を促進するものであり、線維芽細胞の増殖を促進するものではない。また特許文献1には、イトヒメハギエキス等の特定の植物エキス、又はアスコルビン酸等の特定の化合物が、線維芽細胞の増殖を促す結果、コラーゲン、及びヒアルロン酸産生が向上し、皮膚や爪の老化を防止する点については何も開示していない。
本発明は、皮膚中に存在するコラーゲンとヒアルロン酸量を向上させ、シワやタルミを予防、緩和、改善することによって肌の弾力や張りを取り戻すために、コラーゲンやヒアルロン酸を産生する線維芽細胞を増殖する促進剤、及び該線維芽細胞増殖促進剤を含有する皮膚外用剤、浴用剤及び飲食物を提供することを目的としてなされたものである。 The present invention improves the amount of collagen and hyaluronic acid present in the skin, and prevents collagen, hyaluronic acid, and fibroblasts that produce collagen and hyaluronic acid to regain skin elasticity and tension by preventing, mitigating, and improving And an external preparation for skin, bath preparation, and food and drink containing the fibroblast growth promoter.
本発明者らは、上記課題を解決するために鋭意研究を重ねた結果、特定の植物エキス、アルブチン、アスコルビン酸、アルギン酸オリゴ糖類が線維芽細胞の増殖を促進する作用を有することを見出し、この知見に基づき本発明を完成させた。 As a result of intensive studies to solve the above problems, the present inventors have found that specific plant extracts, arbutin, ascorbic acid, and alginic acid oligosaccharides have an action of promoting the proliferation of fibroblasts. The present invention has been completed based on the findings.
すなわち、本発明は、イトヒメハギエキス、クララエキス、シャクヤクエキス、カキエキス、タンジンエキス、ツボクサエキス、プーアルエキス、アルブチン、アスコルビン酸及びアルギン酸オリゴ糖類から選ばれる1種又は2種以上を含有することを特徴とする線維芽細胞増殖促進剤を提供する。
また、本発明は、前記線維芽細胞増殖促進剤を含有することを特徴とする皮膚外用剤、浴用剤又は飲食物を提供する。
That is, the present invention is characterized by containing one or more selected from Itohime extract, Clara extract, peony extract, oyster extract, tanjin extract, camellia extract, puer extract, arbutin, ascorbic acid and alginate oligosaccharides. A fibroblast proliferation promoter is provided.
Moreover, this invention provides the skin external preparation, the bath preparation, or food-drinks characterized by including the said fibroblast proliferation promoter.
イトヒメハギエキス、クララエキス、シャクヤクエキス、カキエキス、タンジンエキス、ツボクサエキス、プーアルエキス、アルブチン、アスコルビン酸及びアルギン酸オリゴ糖類はそれぞれ単独で、特に組み合わせることで線維芽細胞の増殖を促進する作用があり、線維芽細胞増殖促進剤として様々な用途で有用である。これらを配合した化粧品をはじめ、医薬部外品、浴用剤や飲食物を使用又は摂取することにより、線維芽細胞の増殖の効果が期待できるので、皮膚等の老化現象の防止、改善が図られる。 Itohimeha extract, Clara extract, Peonies extract, Oyster extract, Tanjin extract, Clover extract, Puaru extract, Arbutin, Ascorbic acid and Alginate oligosaccharides are each alone, and in particular, have the action of promoting fibroblast proliferation, It is useful in various applications as a fibroblast growth promoter. By using or ingesting cosmetics, quasi-drugs, bath preparations and foods and drinks containing these, the effect of proliferating fibroblasts can be expected, thus preventing and improving the aging phenomenon of the skin and the like. .
本発明の線維芽細胞増殖促進剤は、イトヒメハギエキス、クララエキス、シャクヤクエキス、カキエキス、タンジンエキス、ツボクサエキス、プーアルエキス、アルブチン、アスコルビン酸及びアルギン酸オリゴ糖類から選ばれる1種又は2種以上を含有することを特徴とするものである。 The fibroblast growth promoter according to the present invention comprises one or more selected from the group consisting of citrus extract, clara extract, peony extract, oyster extract, tandin extract, camellia extract, puer extract, arbutin, ascorbic acid and alginate oligosaccharide. It is characterized by containing.
前記植物エキス、アルブチン、アスコルビン酸及びアルギン酸オリゴ糖類から選ばれる2種以上含有する本発明の線維芽細胞増殖促進剤としては、
アルギン酸オリゴ糖類とアルブチン、ツボクサエキス、タンジンエキス、イトヒメハギエキス、カキエキス、クララエキス、又はプーアルエキスとの組み合わせ;
アルブチンとアスコルビン酸、クララエキス、又はプーアルエキスとの組み合わせ;
イトヒメハギエキスとプーアルエキス、タンジンエキス、又はクララエキスとの組み合わせ;
クララエキスとシャクヤクエキス、ツボクサエキス、又はプーアルエキスとの組み合わせ;
シャクヤクエキスとカキエキスとの組み合わせ;
アルギン酸オリゴ糖類、アルブチン、及びカキエキスの組み合わせ;
アルギン酸オリゴ糖類、クララエキス、及びプーアルエキスの組み合わせ;
アルギン酸オリゴ糖類、イトヒメハギエキス、及びクララエキスとの組み合わせ;
アルブチン、クララエキス、及びプーアルエキスの組み合わせ;
カキエキス、クララエキス、及びツボクサエキスの組み合わせ;
イトヒメハギエキス、カキエキス、タンジンエキス、及びツボクサエキスの組み合わせ;
から選ばれる組み合わせを含有するものが、皮膚等の老化現象の防止、改善作用に特に優れることから好ましい。
As the fibroblast proliferation promoter of the present invention containing two or more selected from the plant extract, arbutin, ascorbic acid and alginate oligosaccharides,
A combination of an alginic acid oligosaccharide and arbutin, communis extract, tandin extract, citrus extract, oyster extract, clara extract or puer extract;
A combination of arbutin and ascorbic acid, Clara extract or Puaru extract;
A combination of Itohimehagi extract and Puaru extract, Tanjin extract or Clara extract;
A combination of Clara extract and Peonies extract, Clover extract or Puer extract;
Combination of peony extract and oyster extract;
A combination of alginate oligosaccharide, arbutin and oyster extract;
A combination of alginate oligosaccharides, Clara extract, and puer extract;
A combination of alginate oligosaccharides, Itohime extract, and Clara extract;
A combination of arbutin, clara extract and puer extract;
A combination of oyster extract, Clara extract, and Clover extract;
A combination of Itohimehae extract, oyster extract, tanjin extract, and camellia extract;
Those containing a combination selected from the above are preferable because they are particularly excellent in preventing and improving the aging phenomenon of skin and the like.
本発明で使用するイトヒメハギエキスとは、ヒトハギ科植物のイトヒメハギの根を用いて抽出するが、地上部さらに同属植物を用いて抽出することができる。 The extract of Itohimehae used in the present invention is extracted using the root of Itohimehagi, which is a plant belonging to the human family, but can also be extracted using the above-mentioned genus plant.
本発明で使用するクララエキスとは、マメ科植物のクララの根を用いて抽出するが、地上部さらに同属植物を用いて抽出することができる。 The Clara extract used in the present invention is extracted by using the roots of the leguminous plant Clara, but can be extracted by using the above-mentioned part and a plant belonging to the same genus.
本発明で使用するシャクヤクエキスとは、ボタン科植物のシャクヤクの根の外皮を除去したものを用いて抽出するが、地上部さらに同属植物を用いて抽出することができる。 The peony extract used in the present invention is extracted using a peony root that has been removed from the peony root, but can be extracted from the above-ground part and a plant belonging to the same genus.
本発明で使用するカキエキスとは、カキノキ科植物のカキの葉を用いて抽出するが、地上部さらに同属植物を用いて抽出することができる。 The oyster extract used in the present invention is extracted using oyster leaves of a cynoaceae plant, but can be extracted using the above-mentioned part and a genus plant.
本発明で使用するタンジンエキスとは、シソ科植物のタンジンの根を用いて抽出するが
、地上部さらに同属植物を用いて抽出することができる。
The tanjin extract used in the present invention is extracted using roots of tannins of Labiatae plants, but can be extracted using the above-ground parts and the same genus plants.
本発明で使用するツボクサエキスとは、セリ科植物のツボクサの全草を用いて抽出するが、同属植物を用いて抽出することができる。 The centella extract used in the present invention is extracted by using the whole plant of the celery family plant, but it can be extracted by using a plant belonging to the same genus.
本発明で使用するプーアルエキスとは、ツバキ科植物のチャの葉を黒麹菌などで後発酵させたもの、いわゆるプーアルの葉を用いて抽出する。 The puer extract used in the present invention is extracted by using a so-called puer leaf obtained by post-fermenting tea leaves of a camellia plant with black koji mold or the like.
本発明において、イトヒメハギエキス、クララエキス、シャクヤクエキス、カキエキス、タンジンエキス、ツボクサエキス、プーアルエキスなどの植物エキスとしては、上記の各植物の各種部位を未乾燥のまま又は乾燥させた後そのままに、あるいは、破砕又は粉砕後に搾取して使用することができる。さらに、これらを溶媒で抽出して得られるエキスや、該エキスから抽出溶媒を蒸発又は凍結乾燥して得られる不揮発分を使用することができる。 In the present invention, plant extracts such as Itohime extract, Clara extract, peony extract, oyster extract, tanjin extract, camellia extract, puer extract, etc. Alternatively, it can be used after being crushed or crushed. Furthermore, the extract obtained by extracting these with a solvent, and the non-volatile content obtained by evaporating or lyophilizing the extraction solvent from the extract can be used.
ここで用いられる抽出溶媒としては、水、メタノール、エタノール、エチレングリコール、プロピレングリコール、1,3−ブチレングリコールなどの低級アルコール類、アセトンなどのケトン類、酢酸エチルなどのエステル類、エチルエーテルなどのエーテル類、トルエンなどの芳香族類等の各種の溶媒が挙げられ、単独又は2種以上の溶媒を任意に組み合わせて使用することができる。 Examples of the extraction solvent used here include water, methanol, ethanol, ethylene glycol, propylene glycol, lower alcohols such as 1,3-butylene glycol, ketones such as acetone, esters such as ethyl acetate, and ethyl ether. Various solvents, such as ethers and aromatics, such as toluene, are mentioned, It can use individually or in combination of 2 or more types.
本発明で使用するアルブチンとは、コケモモ、ウワウルシ、ナシなどの植物に含まれる天然型(β−グルコシド型)の配糖体であり、化学名が4−ヒドロキシフェニル−β−D−グルコシピラノシドのものを用いることができる。 Arbutin used in the present invention is a natural type (β-glucoside type) glycoside contained in plants such as cowberry, walrus, and pear, and has a chemical name of 4-hydroxyphenyl-β-D-glucosipyrano. Sid's can be used.
本発明で使用するアスコルビン酸とは、ミカン、レモンなどの柑橘類、キウイ、イチゴ、メロンなどの果物や野菜類等に含まれる水溶性のビタミンで、ビタミンCとも呼ばれる。さらに本発明では、パルミチン酸、ステアリン酸とのモノエステル又はジエステル等の誘導体化したものや、リン酸マグネシウム塩、ナトリウム塩又は配糖体等のアスコルビン酸誘導体も用いることができる。 Ascorbic acid used in the present invention is a water-soluble vitamin contained in citrus fruits such as mandarin orange and lemon, fruits and vegetables such as kiwi, strawberry and melon, and is also called vitamin C. Furthermore, in the present invention, derivatized products such as mono- or diesters with palmitic acid and stearic acid, and ascorbic acid derivatives such as magnesium phosphate, sodium salt or glycoside can also be used.
本発明で使用するアルギン酸オリゴ糖類とは、高分子アルギン酸又は高分子アルギン酸塩(ナトリウム塩、マグネシウム塩、カリウム塩など)を低分子化し、分子量を2000〜20000に調製したものを用いる。そして、その分解方法については、酸又はアルカリ分解、酵素分解、熱分解などの方法で良く、その手法は問わず、また、高分子アルギン酸を低分子アルギン酸とした後、低分子アルギン酸塩にしたものでも良い。 As the alginate oligosaccharide used in the present invention, a polymer alginate or a polymer alginate (sodium salt, magnesium salt, potassium salt, etc.) having a reduced molecular weight and a molecular weight of 2000 to 20000 is used. The decomposition method may be acid or alkali decomposition, enzymatic decomposition, thermal decomposition, etc., regardless of the method, and after converting high molecular alginic acid to low molecular alginic acid, low molecular alginate is used. But it ’s okay.
本発明で使用される植物エキスは、医薬又は民間薬、食品、化粧品の成分として一般的に用いられるものであり、その安全性が確認されているものである。 The plant extract used in the present invention is generally used as a component of medicines or folk medicines, foods and cosmetics, and its safety has been confirmed.
本発明の線維芽細胞増殖促進剤は、前記植物エキス、アルブチン、アスコルビン酸、アルギン酸オリゴ糖類から選ばれる1種又は2種以上を含有し、線維芽細胞増殖促進剤への総配合量はその剤型によっても異なるものであり、蒸発残分をそのまま使用しても構わないし、目的用途によって適宜、配合量を調整すればよく、また、本発明の線維芽細胞増殖促進剤の使用量にも特に制限はなく、用途や適用により適宜調整することができる。 The fibroblast proliferation promoter of the present invention contains one or more selected from the plant extract, arbutin, ascorbic acid, and alginic acid oligosaccharides, and the total amount added to the fibroblast proliferation promoter is the agent. Depending on the type, the evaporation residue may be used as it is, the blending amount may be adjusted as appropriate according to the intended use, and the amount of the fibroblast proliferation promoter of the present invention is particularly used. There is no restriction | limiting, It can adjust suitably with a use or application.
本発明の線維芽細胞増殖促進剤は、外用、内用、素材への処理など様々な形態に適用できる。また、通常の外用、内用素材への処理などで使用されている薬剤などとも組み合わせて使用することができ、併用薬剤により本発明の効果がより発現しやすくなる。
本発明の線維芽細胞増殖促進剤は、医薬品、医薬部外品、局所又は全身用の皮膚化粧品
、頭皮・頭髪に適用する薬用又は化粧用の製剤類をはじめとする各種の皮膚外用剤、浴用剤、飲食物などに配合することができる。
The fibroblast proliferation promoter of the present invention can be applied to various forms such as external use, internal use, and treatment of raw materials. In addition, it can be used in combination with a drug used in normal treatment for external or internal use, etc., and the combined drug makes it easier to express the effect of the present invention.
The fibroblast growth-promoting agent of the present invention is a pharmaceutical, quasi-drug, topical or systemic skin cosmetic, various external preparations for skin, such as medicinal or cosmetic preparations applied to the scalp / hair, for bath It can mix | blend with an agent, food-drinks, etc.
本発明の皮膚外用剤、浴用剤、飲食物は、前記線維芽細胞増殖促進剤の1種又は2種以上を含有する。そして前記線維芽細胞増殖促進剤の皮膚外用剤等への総配合量は、剤型により適宜異なるが、前記皮膚外用剤、浴用剤、飲食物全体の質量に対し、一般的には、前記線維芽細胞促進剤に含有される植物エキス、アルブチン、アスコルビン酸、アルギン酸オリゴ糖類の配合量に換算して、0.01質量%〜10質量%、好ましくは0.025質量%〜5質量%、さらに特定すると0.05質量%〜2.5質量%となるように含有することが望ましい。 The skin external preparation, bath preparation, and food and drink of the present invention contain one or more fibroblast proliferation promoters. The total blending amount of the fibroblast proliferation promoter into the external preparation for skin and the like varies depending on the dosage form, but generally, the fiber for the external preparation for skin, the bath preparation, and the total food and drink is the fiber. In terms of the amount of plant extract, arbutin, ascorbic acid, alginate oligosaccharide contained in the blast promoter, 0.01% by mass to 10% by mass, preferably 0.025% by mass to 5% by mass, If it specifies, it is desirable to contain so that it may become 0.05 mass%-2.5 mass%.
本発明の皮膚外用剤及び浴用剤には、前記線維芽細胞増殖促進剤の他に、通常の皮膚外用剤又は浴用剤において従来から使用されている公知の機能成分、例えば、保湿剤、エモリエント剤、血行促進剤、細胞賦活化剤、抗酸化剤、抗炎症剤、抗菌剤、過酸化物抑制剤などを配合することができる。 The skin external preparation and bath preparation of the present invention include, in addition to the fibroblast proliferation promoter, known functional ingredients conventionally used in normal skin external preparations or bath preparations, such as moisturizers and emollients. , Blood circulation promoters, cell activators, antioxidants, anti-inflammatory agents, antibacterial agents, peroxide inhibitors and the like can be blended.
公知の機能成分としてより具体的には、グリセリン、ブチレングリコール、尿素、アミノ酸類などの保湿剤;スクワラン、マカデミアナッツ油、オリーブ油、ホホバ油、シリコン油などのエモリエント剤;ビタミンE類、トウガラシチンキなどの血行促進剤;核酸などの細胞賦活化剤、ジブチルヒドロキシトルエン(BHT)、ジブチルヒドロキシアニソール(BHA)、酢酸トコフェロールなどの抗酸化剤;グリチルリチン、アラントインなどの抗炎症剤;ヒノキチオール、塩化ベンザルコニウム、クロルヘキシジン塩、パラヒドロキシ安息香酸エステルなどの抗菌剤;スーパーオキシドジスムターゼ(SOD)などの過酸化物抑制剤など、種々の機能成分を配合することができる。
また、オウゴンエキス、イチョウエキス、胎盤抽出物、乳酸菌培養抽出物などの植物・動物・微生物由来の各種抽出物なども制限なく添加して使用することができる。
More specifically, known functional ingredients include humectants such as glycerin, butylene glycol, urea, and amino acids; emollients such as squalane, macadamia nut oil, olive oil, jojoba oil, and silicon oil; vitamin Es, pepper tincture, and the like. Blood circulation promoters: Cell activators such as nucleic acids, antioxidants such as dibutylhydroxytoluene (BHT), dibutylhydroxyanisole (BHA) and tocopherol acetate; anti-inflammatory agents such as glycyrrhizin and allantoin; hinokitiol, benzalkonium chloride, Various functional components such as antibacterial agents such as chlorhexidine salt and parahydroxybenzoate ester; peroxide inhibitors such as superoxide dismutase (SOD) can be blended.
In addition, various extracts derived from plants, animals, and microorganisms such as hornon extract, ginkgo biloba extract, placenta extract, and lactic acid bacteria culture extract can be added and used without limitation.
本発明の皮膚外用剤とは、外用可能な剤であって、その剤型には特に制限はなく、例えば、ペースト剤、クリーム、ジェル、軟膏、ローション、乳液、パック、パウダー、ハップ剤などが例示できる。 The external preparation for skin of the present invention is an agent that can be applied externally, and there is no particular limitation on the dosage form, for example, paste, cream, gel, ointment, lotion, emulsion, pack, powder, haptic agent, etc. It can be illustrated.
本発明の浴用剤の剤型にも特に制限はなく、例えば、粉末、顆粒状などの固形製剤、乳液、ペースト状などの液体製剤などが例示できる。 There is no restriction | limiting in particular also in the dosage form of the bath preparation of this invention, For example, liquid preparations, such as solid preparations, such as a powder and a granular form, an emulsion, and a paste form, etc. can be illustrated.
本発明の飲食物には、前記線維芽細胞増殖促進剤の他に、通常食品に使用されている様々な材料を特に制限なく併用することができる。 In addition to the fibroblast proliferation promoter, various materials that are usually used in foods can be used in the food and drink of the present invention without any particular limitation.
本発明の飲食物の剤型としては適用可能なあらゆる形態があり、例えば、ビスケット、クッキー、錠剤、カプセル剤、キャンディー、ガム、粉末などの固形製剤、飲料などの液体製剤、ゼリーなどの半固形製剤などが例示できる。 The dosage form of the food and drink of the present invention includes all applicable forms, for example, solid preparations such as biscuits, cookies, tablets, capsules, candy, gum, and powder, liquid preparations such as beverages, and semisolids such as jelly Examples include preparations.
また、本発明の皮膚外用剤、浴用剤及び飲食物には、その剤型化のために界面活性剤、油脂類などの基材成分や、必要に応じて増粘剤、防腐剤、等張化剤、酸化防止剤、紫外線吸収剤、キレート剤、香料、着色料などの種々の添加物を併用できる。 In addition, the external preparation for skin, bath preparation and food and drink of the present invention include base ingredients such as surfactants and fats and oils, and thickeners, preservatives, isotonic agents as necessary. Various additives such as an agent, an antioxidant, an ultraviolet absorber, a chelating agent, a fragrance, and a coloring agent can be used in combination.
上記の界面活性剤としては、特に限定されるものではないが、一般的な非イオン界面活性剤、陰イオン界面活性剤、陽イオン界面活性剤、両性界面活性剤を用いることができる。例えば、高級アルコールのアルキレンオキサイド付加物、高級アルキルアミンのアルキレンオキサイド付加物、高級脂肪酸のアルキレンオキサイド付加物、高級脂肪酸アミドのアルキレンオキサイド付加物、多価アルコールの脂肪酸エステル、硬化ひまし油のアルキレンオキサイド付加物、ポリエチレングリコールソルビタンアルキルエステル、ステロール等のアルキレンオキサイド付加物などの非イオン界面活性剤;アルキル硫酸ナトリウム、アルキロイルメチルタウリンナトリウム、α−オレフィンスルホン酸ナトリウム、ポリオキシアルキレンアルキルエーテル硫酸ナトリウムなどの陰イオン界面活性剤;塩化アルキルピリジニウム、塩化ジステアリルジメリルアンモニウムなどの陽イオン界面活性剤;アミノプロピオン酸ナトリウム、アルキルポリアミノエチルグリシンなどの両性界面活性剤が挙げられる。そして、これらの界面活性剤は1種又は2種以上を選択して使用することができる。 The surfactant is not particularly limited, and general nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants can be used. For example, alkylene oxide adduct of higher alcohol, alkylene oxide adduct of higher alkylamine, alkylene oxide adduct of higher fatty acid, alkylene oxide adduct of higher fatty acid amide, fatty acid ester of polyhydric alcohol, alkylene oxide adduct of hardened castor oil , Nonionic surfactants such as alkylene oxide adducts such as polyethylene glycol sorbitan alkyl esters and sterols; anions such as sodium alkyl sulfate, sodium alkylylmethyl taurate, sodium α-olefin sulfonate, sodium polyoxyalkylene alkyl ether sulfate Surfactants; Cationic surfactants such as alkylpyridinium chloride and distearyl dimerylammonium chloride; Sodium aminopropionate Amphoteric surfactants such as alkylpolyaminoethylglycine the like. And these surfactant can select and use 1 type (s) or 2 or more types.
本発明において使用可能な基材成分として、特に限定されるものではないが、例えば、オリーブ油、ツバキ油、アボカド油、マカデミアナッツ油、杏仁油、ホホバ油、スクワラン、スクワレン、馬油、パラフィン、シリコンなど、一般的に知られている油脂類が挙げられる。 The base material component usable in the present invention is not particularly limited, and examples thereof include olive oil, camellia oil, avocado oil, macadamia nut oil, apricot oil, jojoba oil, squalane, squalene, horse oil, paraffin, and silicon. And generally known fats and oils.
本発明において使用可能な増粘剤として、特に限定されるものではないが、例えば、ポリビニルアルコール、ポリビニルアクリルアミド、ポリエチレングリコール、及びこれらの各種誘導体;ヒドロキシアルキルセルロースなどのセルロース類及びその誘導体;デキストラン、ゼラチン、アラビアガム、トラガントガムなどのガム類;カルボキシビニルポリマーなどの水溶性高分子などが挙げられる。 Although it does not specifically limit as a thickener which can be used in this invention, For example, polyvinyl alcohol, polyvinyl acrylamide, polyethyleneglycol, and these various derivatives; Celluloses, such as a hydroxyalkyl cellulose, and its derivative; Dextran, Examples include gums such as gelatin, gum arabic, and gum tragacanth; and water-soluble polymers such as carboxyvinyl polymer.
本発明において使用可能な防腐剤として、特に限定されるものではないが、例えば、パラヒドロキシ安息香酸エステル、パラオキシ安息香酸塩とその誘導体、フェノキシエタノール、ヒノキチオール、塩化ベンザルコニウム、クロルヘキシジン塩などが挙げられる。 Examples of the preservative that can be used in the present invention include, but are not limited to, parahydroxybenzoic acid esters, paraoxybenzoates and their derivatives, phenoxyethanol, hinokitiol, benzalkonium chloride, chlorhexidine salts, and the like. .
本発明において使用可能な等張化剤として、特に限定されるものではないが、例えば、塩化ナトリウム、塩化カリウム、塩化カルシウムなどの無機塩類が挙げられる。 The isotonic agent that can be used in the present invention is not particularly limited, and examples thereof include inorganic salts such as sodium chloride, potassium chloride, and calcium chloride.
本発明において使用可能な紫外線吸収剤として、特に限定されるものではないが、例えば、パラアミノ安息香酸、ベンゾフェノン系紫外線吸収剤、ベンゾトリアゾール系紫外線吸収剤などが挙げられる。 Although it does not specifically limit as an ultraviolet absorber which can be used in this invention, For example, a para amino benzoic acid, a benzophenone series ultraviolet absorber, a benzotriazole type ultraviolet absorber, etc. are mentioned.
本発明において使用可能なキレート剤として、特に限定されるものではないが、例えば、エチレンジアミン四酢酸、フィチン酸、クエン酸及びこれらの水溶性塩などが挙げられる。 Although it does not specifically limit as a chelating agent which can be used in this invention, For example, ethylenediaminetetraacetic acid, phytic acid, a citric acid, these water-soluble salts, etc. are mentioned.
以下、本発明を更に詳しく説明するために実施例によって説明するが、本発明はこれらの実施例により何ら限定されるものではない。
(1)植物エキスの製造方法
植物エキスは、以下の表1に示す各植物の各部位を、50質量%エタノール水溶液の環流下で1時間かけて抽出後ろ過し、得られた抽出液から水、エタノールを減圧留去して各植物エキスを得た。得られた植物エキスを以下に示す実施例に使用した。
(1) Production method of plant extract The plant extract is filtered after extracting each part of each plant shown in Table 1 below under reflux of 50% by mass ethanol aqueous solution for 1 hour, and water is extracted from the obtained extract. Ethanol was distilled off under reduced pressure to obtain each plant extract. The obtained plant extract was used for the Example shown below.
(2)アルギン酸オリゴ糖類の製造方法
市販のアルギン酸ナトリウムであるSKAT−ULV(キミカ社製)1.5g、リン酸アンモニウム0.05g、酵母エキス0.01g、塩化ナトリウム2gをイオン交換水100g中に溶解させ、オートクレーブで2.1atm、121℃、20分間の滅菌操作を行った。滅菌処理後のアルギン酸溶液に対し、アルギン酸分解菌であるPseudo alteromonas haloplanctic(ITM 222)を一白金耳埴菌し、室温下、8時間前培養を行った。
(2) Production method of alginic acid oligosaccharide 1.5 g of commercially available sodium alginate SKAT-ULV (manufactured by Kimika), 0.05 g of ammonium phosphate, 0.01 g of yeast extract, and 2 g of sodium chloride in 100 g of ion-exchanged water Dissolved and sterilized by autoclave at 2.1 atm, 121 ° C. for 20 minutes. The alginate solution after sterilization was platinized with Pseudoalteromonas halloplastic (ITM 222), which is an alginate-degrading bacterium, and precultured at room temperature for 8 hours.
次に、得られた前培溶液1mLを、アルギン酸ナトリウム分解用培地(リン酸アンモニウム0.15g、酵母エキス0.01g、アルギン酸ナトリウム(キミカ社製)9.0g、塩化ナトリウム6.0gをイオン交換水300gに溶解させ、オートクレーブで2.1atm、121℃、20分間の滅菌操作を行ったものを使用)に添加後、室温条件下で48時間振とう培養を行った。 Next, 1 mL of the obtained preculture solution was ion-exchanged with sodium alginate decomposition medium (0.15 g of ammonium phosphate, 0.01 g of yeast extract, 9.0 g of sodium alginate (manufactured by Kimika), 6.0 g of sodium chloride) It was dissolved in 300 g of water and added to an autoclave that had been sterilized at 2.1 atm, 121 ° C. for 20 minutes, and then cultured with shaking at room temperature for 48 hours.
振とう培養後のアルギン酸ナトリウム分解液から、菌体除去のための遠心分離操作(10000rpm×10分間)を行い、上澄み液を得た。得られた上澄み液に液量と同量のメタノールを加え、分解後のアルギン酸ナトリウム溶液から高分子量(数万)のアルギン酸ナトリウムを沈降させて濾別し、低分子量のアルギン酸オリゴ糖ナトリウムを含有している濾液を得た。 From the sodium alginate decomposition solution after shaking culture, a centrifugal separation operation (10000 rpm × 10 minutes) was performed to remove the cells, and a supernatant was obtained. Add the same amount of methanol to the resulting supernatant, precipitate high molecular weight (tens of thousands) sodium alginate from the decomposed sodium alginate solution, and filter and contain low molecular weight sodium alginate oligosaccharides. A filtrate was obtained.
アルギン酸オリゴ糖ナトリウムを含有している濾液の中から塩化ナトリウムなどの不純物を除去し、精製を行うために、ゲル濾過操作(Sephadex LH−20、Pharmacia Fine Chemicals)を行った。ゲル濾過操作後、得られた液を濃縮して、凍結乾燥機で乾燥を行い、目的とするアルギン酸オリゴ糖ナトリウム(重量平均分子量約2000)を5.4g(収率60%)得た。 To remove impurities such as sodium chloride from the filtrate containing sodium alginate oligosaccharide and perform purification, gel filtration operation (Sephadex LH-20, Pharmacia Fine Chemicals) was performed. After the gel filtration operation, the obtained liquid was concentrated and dried with a freeze dryer to obtain 5.4 g (yield 60%) of the desired sodium alginate oligosaccharide (weight average molecular weight: about 2000).
また、振とう培養時間を48時間から8時間に換えた以外は上記と同様に操作して、重量平均分子量約20000のアルギン酸オリゴ糖ナトリウムを得た。
更には、得られた重量平均分子量約2000のアルギン酸オリゴ糖ナトリウムをイオン交換樹脂(アンバーライト1006F H、ローム・アンド・ハース・ジャパン社製)と共に操作して、重量平均分子量約2000のアルギン酸オリゴ糖を得た。
In addition, the alginate oligosaccharide sodium having a weight average molecular weight of about 20000 was obtained in the same manner as described above except that the shaking culture time was changed from 48 hours to 8 hours.
Further, the obtained sodium alginate oligosaccharide having a weight average molecular weight of about 2000 is operated together with an ion exchange resin (Amberlite 1006F H, manufactured by Rohm and Haas Japan) to obtain an alginate oligosaccharide having a weight average molecular weight of about 2000. Got.
なお、重量平均分子量の測定は、水系ゲルパーミッションクロマトグラフィー装置GPC−8020(東ソー(株)製)を用いて測定した。測定条件は、カラムにG3000(東ソー(株)製)とG5000(東ソー(株)製)を直結して用い 、カラム温度40℃、カラム流量1.0ml/min、溶出液0.1M NaCl水溶液、RI検出であり、重量平均分子量はPEG(ポリエチレングリコール)を標品として換算した値である。 The weight average molecular weight was measured using an aqueous gel permeation chromatography apparatus GPC-8020 (manufactured by Tosoh Corporation). The measurement conditions were such that G3000 (manufactured by Tosoh Corp.) and G5000 (manufactured by Tosoh Corp.) were directly connected to the column, the column temperature was 40 ° C., the column flow rate was 1.0 ml / min, the eluent 0.1M NaCl aqueous solution, RI detection, and the weight average molecular weight is a value obtained by converting PEG (polyethylene glycol) as a standard.
得られたアルギン酸オリゴ糖ナトリウム、アルギン酸オリゴ糖を以下に示す実施例に使用した。 The obtained sodium alginate oligosaccharide and alginate oligosaccharide were used in the following examples.
(3)アルブチン
和光純薬工業(株)製のアルブチンを以下に示す実施例に使用した。
(4)アスコルビン酸
和光純薬工業(株)製のL(+)−アスコルビン酸を以下に示す実施例に使用した。
(3) Arbutin Arbutin manufactured by Wako Pure Chemical Industries, Ltd. was used in the following examples.
(4) Ascorbic acid L (+)-ascorbic acid manufactured by Wako Pure Chemical Industries, Ltd. was used in the examples shown below.
(I)線維芽細胞増殖促進剤
[実施例1]
アルブチンを10mg/mLとなるよう調整し、その後、クリーンベンチ内で0.2μmのシリンジフィルターを用いて滅菌した。そして、滅菌精製水を加えて2mg/mLとなるよう調整して、培地に添加するアルブチンの希釈液を作製した。
次に、倉敷紡績(株)製の正常ヒト皮膚線維芽細胞を規定の調製法に基づき、分化、培養を行った。培地には、低血清増殖添加剤(LSGS)を添加した正常ヒト皮膚線維芽細胞増殖用低血清培地(Medium106S)を用いた。
培地に正常ヒト成人線維芽細胞(500000cell/mL)の溶液を播種し、37℃、5%−CO2、加湿のインキュベーターに入れ、1日おきに培地を交換し、6日間培養した。
6日後、シャーレから細胞をはがし、細胞浮遊液を作成した(15000cell/mL)。細胞浮遊液を24well plateに1mLずつ播種し、2日間培養した。培地交換の際、前記アルブチンの希釈液を10μL(最終濃度が20μg/mLとなる)添加し、さらに2日間培養した。2日おきに培地交換等を行い、細胞播種8日目に培地を回収した後、細胞は1mol/Lの水酸化ナトリウムではがし、Lowry法にてタンパク質の量を測定した。
(I) Fibroblast proliferation promoter [Example 1]
Arbutin was adjusted to 10 mg / mL, and then sterilized using a 0.2 μm syringe filter in a clean bench. Then, sterilized purified water was added to adjust to 2 mg / mL to prepare a diluted solution of arbutin to be added to the medium.
Next, normal human dermal fibroblasts manufactured by Kurashiki Boseki Co., Ltd. were differentiated and cultured according to a prescribed preparation method. The medium used was a low serum medium (Medium 106S) for normal human skin fibroblast proliferation supplemented with a low serum growth additive (LSGS).
The medium was seeded with a solution of normal human adult fibroblasts (500000 cells / mL), placed in a humidified incubator at 37 ° C., 5% -CO 2 , the medium was changed every other day, and cultured for 6 days.
Six days later, cells were peeled from the petri dish to prepare a cell suspension (15000 cell / mL). 1 mL of the cell suspension was seeded on a 24-well plate and cultured for 2 days. At the time of medium exchange, 10 μL of the diluted arbutin solution (final concentration becomes 20 μg / mL) was added, and further cultured for 2 days. The medium was changed every two days, and the medium was collected on the 8th day after cell seeding. Then, the cells were peeled off with 1 mol / L sodium hydroxide, and the amount of protein was measured by the Lowry method.
この時のタンパク質の量は、線維芽細胞増殖促進成分(アルブチン)の希釈液の代わりに滅菌精製水を添加して、その他は同様の操作をした比較例1のタンパク質の量と比較したところ125%であり、25%増加していた。このタンパク質は線維芽細胞由来のものであり、細胞増殖の指標となり、タンパク質量の増加は線維芽細胞が増殖していることを反映している。 The amount of the protein at this time was 125 when compared with the amount of the protein of Comparative Example 1 in which sterilized purified water was added instead of the diluted solution of the fibroblast growth promoting component (arbutin) and the other operations were the same. %, An increase of 25%. This protein is derived from fibroblasts and serves as an index of cell proliferation, and an increase in the amount of protein reflects the proliferation of fibroblasts.
[実施例2〜40]
線維芽細胞増殖促進成分及び添加した最終濃度を表2のように換えた以外は実施例1と同様の操作をして得られたタンパク質の量と、比較例1のタンパク質の量とを比較した結果を表2に示す。
[Examples 2 to 40]
The amount of protein obtained by the same operation as in Example 1 except that the fibroblast growth promoting component and the added final concentration were changed as shown in Table 2 were compared with the amount of protein in Comparative Example 1. The results are shown in Table 2.
表2に示すように、線維芽細胞増殖促進成分として実施例1〜40の各種植物エキス、アルブチン、アスコルビン酸、アルギン酸オリゴ糖類から選ばれる1種又は2種以上の組成物を用いたものは、線維芽細胞に対し有意に増殖促進効果を示していることがわかる。 As shown in Table 2, those using one or more compositions selected from the various plant extracts of Examples 1 to 40, arbutin, ascorbic acid, and alginate oligosaccharides as the fibroblast proliferation promoting component are as follows: It can be seen that the effect of promoting the proliferation of fibroblasts is significant.
(II)皮膚外用剤の処方例
表3〜14に示す組成で線維芽細胞増殖促進剤を配合した皮膚外用剤(化粧水、乳液、クリーム、ボディクリーム)の処方を調製した。調製方法は下記の通りである。なお、配合量の単位はgで、表中の精製水の「残量」とは全量を100gとする量である。
(II) Formulation example of external preparation for skin Formulation of external preparation for skin (skin lotion, milky lotion, cream, body cream) formulated with a fibroblast growth promoter with the composition shown in Tables 3-14 was prepared. The preparation method is as follows. The unit of the blending amount is g, and the “remaining amount” of purified water in the table is an amount that makes the total amount 100 g.
化粧水(実施例41〜62、比較例2)
表3〜5のA成分、B成分のそれぞれを80℃で加温して溶解し、B成分をA成分に撹拌しながら徐々に加えて乳化した。その後撹拌しながら冷却し、40℃でC成分を加えて、35℃で調製を終了した。
Lotion (Examples 41-62, Comparative Example 2)
Each of A component and B component of Tables 3-5 was heated and melt | dissolved at 80 degreeC, and B component was gradually added and emulsified to A component, stirring. Thereafter, the mixture was cooled with stirring, C component was added at 40 ° C, and the preparation was completed at 35 ° C.
乳液(実施例63〜84、比較例3)
表6〜8のD成分、E成分のそれぞれを80℃に加温して溶解し、D成分をE成分に攪拌しながら加え、均一とした後、ホモミキサーで乳化した。ハンドルミキサーで攪拌しながら冷却し、40℃以下でF成分を加えて、調製を終了した。
Latex (Examples 63 to 84, Comparative Example 3)
Each of D component and E component of Tables 6-8 was heated and melt | dissolved at 80 degreeC, and D component was added to E component, stirring, and after making it uniform, it emulsified with the homomixer. The mixture was cooled while stirring with a handle mixer, and the F component was added at 40 ° C. or lower to complete the preparation.
クリーム(実施例85〜106、比較例4)
表9〜11のG成分、H成分をそれぞれ75℃に加温して溶解し、G成分をパドルミキサーで撹拌しながらH成分を少量ずつ加えた。その後、撹拌しながら冷却し、40℃でI成分を加えた後、約35℃で調製を終了した。
Cream (Examples 85-106, Comparative Example 4)
The G component and the H component in Tables 9 to 11 were each dissolved by heating to 75 ° C., and the H component was added little by little while stirring the G component with a paddle mixer. Then, it cooled, stirring, and added I component at 40 degreeC, Then, preparation was complete | finished at about 35 degreeC.
ボディクリーム(実施例107〜128、比較例5)
表12〜14のJ成分、K成分をそれぞれ75℃に加温して、J成分をパドルミキサーで撹拌しながらK成分を少量ずつ加えた。その後、撹拌しながら冷却し、45℃以下でL成分を加えて調製を終了した。
Body cream (Examples 107 to 128, Comparative Example 5)
The J component and the K component in Tables 12 to 14 were each heated to 75 ° C., and the K component was added little by little while stirring the J component with a paddle mixer. Then, it cooled, stirring, and added L component at 45 degrees C or less, and complete | finished preparation.
評 価
前記実施例41〜128、比較例2〜5の皮膚外用剤について、それぞれ女性2名ずつの(23群×4処方)計184名に対して毎日、朝と夜の2回、適量を肌に塗布することを1ヶ月間続けるモニター試験を行い、その使用感を調べた。下記の基準にて評価を行った結果を表15に示す。なお、使用期間中に皮膚の異常を訴えたものはいなかった。
有 効 :肌のハリ・ツヤ・弾力が増した
やや有効:肌のハリ・ツヤ・弾力がやや増した
効果無し:使用前と変化無し
Evaluation About the external preparations for skin of Examples 41 to 128 and Comparative Examples 2 to 5, appropriate amounts were given twice a day in the morning and at night for a total of 184 people each (2 groups of 23 women x 4). A monitor test was conducted in which application to the skin was continued for one month, and the feeling of use was examined. Table 15 shows the results of evaluation based on the following criteria. None of the patients complained of skin abnormalities during the period of use.
Effective: Skin elasticity, gloss, elasticity increased slightly Effective: Skin elasticity, gloss, elasticity increased slightly No effect: No change from before use
本発明の線維芽細胞増殖促進剤を配合した実施例41〜128の皮膚外用剤では、線維芽細胞増殖促進効果により肌のハリ・ツヤ・弾力が増した。一方、本発明の線維芽細胞増殖促進剤を添加していない比較例2〜5の皮膚外用剤では、肌のハリ・ツヤ・弾力性が使用前とは変化がなかったことから、本発明の皮膚外用剤ではいずれも皮膚の老化現象の改善が図られる。 In the skin external preparations of Examples 41 to 128 containing the fibroblast proliferation promoter of the present invention, the firmness, gloss and elasticity of the skin increased due to the fibroblast proliferation promoting effect. On the other hand, in the external preparations for skin of Comparative Examples 2 to 5 to which the fibroblast proliferation promoter of the present invention was not added, the firmness, gloss and elasticity of the skin were not changed from before use. All external preparations for skin can improve the aging phenomenon of the skin.
(III)皮膚(頭髪)用外用剤の処方
次に、表16〜18に示す組成で線維芽細胞増殖促進剤を配合した皮膚(頭髪)用外用剤(シャンプー、コンディショナー、ヘアトニック)の処方を調製した。調製方法は下記の通りである。なお、配合量の単位はgで、表中の精製水の「残量」とは全量を100gとする量である。
(III) Formulation of external preparation for skin (head hair) Next, prescription of external preparation for skin (hair) (shampoo, conditioner, hair tonic) blended with a fibroblast growth promoter with the composition shown in Tables 16-18. Prepared. The preparation method is as follows. The unit of the blending amount is g, and the “remaining amount” of purified water in the table is an amount that makes the total amount 100 g.
シャンプー(実施例129〜150、比較例6)
表16〜18のM成分を75℃に加温し、撹拌しながら35℃まで冷却した。その後、撹拌を続けながらN成分を加えて、pH調整、粘度調整を行った。さらにO成分を加えて、調製を終了した。
Shampoo (Examples 129 to 150, Comparative Example 6)
The M components in Tables 16 to 18 were heated to 75 ° C and cooled to 35 ° C while stirring. Then, N component was added, continuing stirring, and pH adjustment and viscosity adjustment were performed. Further, O component was added to complete the preparation.
コンディショナー(実施例151〜172、比較例7)
表19〜21のP成分、Q成分をそれぞれ75℃に加温し、P成分をパドルミキサーで撹拌しながら、Q成分を少量ずつ加えた。その後、パドルミキサーで撹拌しながら冷却して、45℃以下でR成分を加えて調製を終了した。
Conditioner (Examples 151-172, Comparative Example 7)
P component and Q component of Tables 19-21 were each heated to 75 degreeC, and Q component was added little by little, stirring P component with a paddle mixer. Then, it cooled, stirring with a paddle mixer, and R component was added at 45 degrees C or less, and preparation was completed.
ヘアトニック(実施例173〜194、比較例8)
表22〜24のS成分、T成分、U成分の全てを40℃に暖めて混合した。
Hair tonic (Examples 173 to 194, Comparative Example 8)
All of the S component, the T component, and the U component in Tables 22 to 24 were warmed to 40 ° C. and mixed.
評 価
前記実施例129〜194、比較例6〜8の皮膚(頭髪)用外用剤について、それぞれ男女1名ずつの(23群×3処方)計138名に対して、シャンプー及びコンディショナーについては毎日の入浴時に洗髪又はコンディショニング剤として頭髪に適量使用し、ヘアトニックについては毎日の入浴後又は朝に頭皮又は頭髪に適量使用して、これを1ヶ月間続けるモニター試験を行い、その使用感を調べた。下記の基準にて評価を行った結果を表25に示す。なお、使用期間中に皮膚の異常を訴えたものはいなかった。
有効:頭皮のハリ・ツヤ・弾力が増した又は頭髪が健やかになった
やや有効:頭皮のハリ・ツヤ・弾力がやや増した又は頭髪がやや健やかになった
効果無し:使用前と変化無し
Evaluation With regard to the external preparations for skin (hair) of Examples 129 to 194 and Comparative Examples 6 to 8, 138 shampoos and conditioners were used daily for each of 138 people (23 groups × 3 prescriptions) for one male and one female. Use a suitable amount for hair as a hair washing or conditioning agent during bathing, and use a suitable amount for hair tonic after daily bathing or in the morning on the scalp or hair, and conduct a monitoring test for one month to examine the feeling of use. It was. Table 25 shows the results of evaluation based on the following criteria. None of the patients complained of skin abnormalities during the period of use.
Effective: Scalp firmness, gloss, elasticity increased or hair became healthy Slightly effective: Scalp elasticity, gloss, elasticity increased slightly or hair became slightly healthy No effect: No change from before use
本発明の線維芽細胞増殖促進剤を配合した実施例129〜194の皮膚(頭髪)用外用剤では、頭皮のハリ・ツヤ・弾力が増すか又はやや増し、また、頭髪が健やかになったか又はやや健やかになって、線維芽細胞増殖促進効果による老化現象の改善が認められた。一方、比較例6〜8の皮膚(頭髪)用外用剤では、頭皮又は頭髪が使用前と変化無しとの評価であったことから、本発明の皮膚(頭髪)用外用剤の効果はいずれも有意であった。 In the external preparation for skin (head hair) of Examples 129 to 194 formulated with the fibroblast proliferation promoter of the present invention, the scalp was increased or slightly increased in elasticity, gloss, elasticity, and the hair became healthy or Slightly healthy and improved aging due to the effect of promoting fibroblast proliferation was observed. On the other hand, in the external preparations for skin (hair) of Comparative Examples 6 to 8, since the scalp or the hair was evaluated before use and no change, the effects of the external preparation for skin (hair) of the present invention are all. It was significant.
(IV)皮膚(爪)用外用剤の処方
次に、表26〜28に示す組成で線維芽細胞増殖促進剤を配合した皮膚(爪)用外用剤(ネイル用トリートメントクリーム)の処方を調製した。調製方法は下記の通りである。なお、配合量の単位はgで、表中の精製水の「残量」とは全量を100gとする量である。
(IV) Formulation of external preparation for skin (nail) Next, a formulation of external preparation for skin (nail) (treatment cream for nail) containing a fibroblast proliferation promoter with the composition shown in Tables 26 to 28 was prepared. . The preparation method is as follows. The unit of the blending amount is g, and the “remaining amount” of purified water in the table is an amount that makes the total amount 100 g.
ネイル用トリートメントクリーム(実施例195〜216、比較例9)
表26〜28のV成分、W成分ともに80℃に加温溶解して、V成分をホモミキサーで撹拌しながらW成分を加えて乳化した。乳化後、X成分を加えて均一になるまで撹拌した後、更にY成分を加えて撹拌混合した。その後、冷却しながら40℃になるまで撹拌し、Z成分を加えて35℃で調製を終了した。
Nail treatment cream (Examples 195 to 216, Comparative Example 9)
Both V component and W component of Tables 26 to 28 were dissolved by heating at 80 ° C., and the W component was added and emulsified while stirring the V component with a homomixer. After emulsification, the X component was added and stirred until uniform, then the Y component was further added and stirred and mixed. Then, it stirred until it became 40 degreeC, cooling, added Z component, and complete | finished preparation at 35 degreeC.
評 価
前記実施例195〜216、比較例9の皮膚(爪)用外用剤について、それぞれ女性3名ずつの(23群)計69名に対して、爪の周囲に上記ネイル用トリートメントクリームを適量塗布することを1ヶ月間続けるモニター試験を行い、その使用感を調べた。下記の基準にて評価を行った結果を表29に示す。なお、使用期間中に皮膚の異常を訴えたものはいなかった。
有 効 :爪のツヤ・弾力が増した
やや有効:爪のツヤ・弾力がやや増した
効果無し:使用前と変化無し
Evaluation Regarding the external preparations for skin (nails) of Examples 195 to 216 and Comparative Example 9, the appropriate amount of the above nail treatment cream is provided around the nails for 69 women (3 groups) each (23 groups). A monitor test was carried out to continue application for one month, and the feeling of use was examined. Table 29 shows the results of evaluation based on the following criteria. None of the patients complained of skin abnormalities during the period of use.
Effective: Increased gloss / elasticity of nails Slightly effective: Increased gloss / elasticity of nails No effect: No change before use
本発明の線維芽細胞増殖促進剤を配合した実施例195〜216の皮膚(爪)用外用剤では、爪のツヤ・弾力が増すか又はやや増すとの評価結果であり、線維芽細胞増殖促進効果による老化現象の改善が認められた。一方、比較例9の皮膚(爪)用外用剤では、爪のツヤ・弾力は使用前と変化無しとの評価であったことから、本発明の皮膚(爪)用外用剤の効果はいずれも有意であった。 In the external preparation for skin (nail) of Examples 195 to 216, in which the fibroblast proliferation promoter of the present invention is blended, it is an evaluation result that the gloss / elasticity of the nail is increased or slightly increased, and the fibroblast proliferation promotion The improvement of the aging phenomenon by the effect was recognized. On the other hand, in the external preparation for skin (nail) of Comparative Example 9, since the gloss and elasticity of the nail were evaluated before use and no change, the effects of the external preparation for skin (nail) of the present invention were all It was significant.
(V)浴用剤の処方例
表30〜32、表34〜36に示す組成で線維芽細胞増殖促進剤を配合した浴用剤(入浴剤、ボディソープ)の処方を調製した。調製方法は下記の通りである。なお、配合量の単位はgで、表中の精製水の「残量」とは全量を100gとする量である。
(V) Formulation examples of bath preparations Formulations of bath preparations (bathing agents, body soaps) containing fibroblast proliferation promoters having the compositions shown in Tables 30 to 32 and Tables 34 to 36 were prepared. The preparation method is as follows. The unit of the blending amount is g, and the “remaining amount” of purified water in the table is an amount that makes the total amount 100 g.
入浴剤(実施例217〜238、比較例10)
表30〜32のAA成分とAB成分をそれぞれ均一になるまで混合した後、AA成分とAB成分とを混合し、さらに均一になるまで充分混合した。
Bath agent (Examples 217 to 238, Comparative Example 10)
The AA component and the AB component in Tables 30 to 32 were mixed until they were uniform, then the AA component and the AB component were mixed, and mixed well until they became more uniform.
評 価
前記実施例217〜238、比較例10の入浴剤について、それぞれ男女1名ずつの(23群)計46名に対して、毎日の入浴時にお湯180Lに対して入浴剤30mLを溶かして入浴することを1ヶ月間続けるモニター試験を行い、その使用感を調べた。下記の基準にて評価を行った結果を表33に示す。なお、使用期間中に皮膚の異常を訴えたものはいなかった。
有 効 :肌のハリ・ツヤ・弾力が増した
やや有効:肌のハリ・ツヤ・弾力がやや増した
効果無し:使用前と変化無し
Evaluation Regarding the bathing agents of Examples 217 to 238 and Comparative Example 10 above, a total of 46 people (one group of 23) each for males and females were bathed by dissolving 30 mL of bathing agent in 180 L of hot water during daily bathing. A monitoring test was conducted for one month, and the feeling of use was examined. Table 33 shows the results of the evaluation based on the following criteria. None of the patients complained of skin abnormalities during the period of use.
Effective: Skin elasticity, gloss, elasticity increased slightly Effective: Skin elasticity, gloss, elasticity increased slightly No effect: No change from before use
本発明の線維芽細胞増殖促進剤を配合した実施例217〜238の入浴剤では、肌のハリ・ツヤ・弾力が増すか又はやや増すとの評価結果であり、線維芽細胞増殖促進効果による老化現象の改善が認められた。一方、比較例10の入浴剤では、肌のハリ・ツヤ・弾力は使用前と変化無しとの評価であったことから、本発明の入浴剤の効果はいずれも有意であった。 The bathing agents of Examples 217 to 238 containing the fibroblast proliferation promoter of the present invention are the results of evaluation that the firmness, gloss, and elasticity of the skin are increased or slightly increased, and aging due to the fibroblast proliferation promoting effect An improvement in the phenomenon was observed. On the other hand, the effects of the bathing agent of the present invention were significant in the bathing agent of Comparative Example 10 because the skin firmness, glossiness and elasticity were evaluated before use and unchanged.
ボディソープ(実施例239〜260、比較例11)
表34〜36のAC成分を80℃に加温し石鹸を作った後、AD成分を順次加えて溶解した。その後、冷却しながら40℃でAE成分を加えて、35℃で調製を終了した。
Body soap (Examples 239 to 260, Comparative Example 11)
The AC components in Tables 34 to 36 were heated to 80 ° C. to make soap, and then AD components were sequentially added and dissolved. Then, AE component was added at 40 degreeC, cooling, and preparation was complete | finished at 35 degreeC.
評 価
前記実施例239〜260、比較例11のボディソープについて、それぞれ女性3名ずつの(23群)、計69名に対して、毎日の入浴時にボディソープとして適量使用することを1ヶ月間続けるモニター試験を行い、その使用感を調べた。
下記の基準にて評価を行った結果を表37に示す。なお、使用期間中に皮膚の異常を訴えたものはいなかった。
有 効 :肌のハリ・ツヤ・弾力が増した
やや有効:肌のハリ・ツヤ・弾力がやや増した
効果無し:使用前と変化無し
Evaluation With respect to the body soaps of Examples 239 to 260 and Comparative Example 11, 3 women each (23 groups), a total of 69 people, used a proper amount as a body soap during daily bathing for 1 month. A continuous monitor test was conducted to examine its feeling of use.
Table 37 shows the results of evaluation based on the following criteria. None of the patients complained of skin abnormalities during the period of use.
Effective: Skin elasticity, gloss, elasticity increased slightly Effective: Skin elasticity, gloss, elasticity increased slightly No effect: No change from before use
本発明の線維芽細胞増殖促進剤を配合した実施例239〜260のボディソープでは、肌のハリ・ツヤ・弾力が増すか又はやや増すとの評価結果であり、線維芽細胞増殖促進効果による老化現象の改善が認められた。一方、比較例11の入浴剤では、肌のハリ・ツヤ・弾力は使用前と変化無しとの評価であったことから、本発明の入浴剤の効果はいずれも有意であった。 In the body soaps of Examples 239 to 260 containing the fibroblast proliferation promoter of the present invention, the evaluation results show that the firmness, gloss and elasticity of the skin are increased or slightly increased, and aging due to the effect of promoting fibroblast proliferation An improvement in the phenomenon was observed. On the other hand, the effects of the bathing agent of the present invention were significant in the bathing agent of Comparative Example 11 because the skin firmness, glossiness and elasticity were evaluated before use and unchanged.
(VI)飲食物の処方例
次に、表38〜41に示す組成で線維芽細胞増殖促進剤を配合した飲食物(パン、サプリメント(錠剤))の処方を調製した。調製方法は下記の通りである。なお、配合量の単位はgで、表中の水の「残量」とは全量を100gとする量である。
(VI) Formulation example of foods and drinks Next, foods and beverages (bread and supplements (tablets)) formulated with a fibroblast growth promoter with the compositions shown in Tables 38 to 41 were prepared. The preparation method is as follows. The unit of the blending amount is g, and the “remaining amount” of water in the table is an amount that makes the total amount 100 g.
パン(実施例261〜270、比較例12)
表38〜39のAF成分全部を混ぜ合わせものに、40℃に加温したAG成分とAH成分を混ぜ合わせたもの加えて、均一になった時点でよくこねた。35℃で40分一次発酵させ、空気を抜くように再度こねた。40℃で40分二次発酵後、180℃で25分間焼いた。
Bread (Examples 261 to 270, Comparative Example 12)
A mixture of all the AF components in Tables 38 to 39 was added to the mixture of the AG component and AH component heated to 40 ° C. and kneaded well when the mixture became uniform. Primary fermentation was carried out at 35 ° C. for 40 minutes, and kneaded again so as to remove air. After secondary fermentation at 40 ° C. for 40 minutes, it was baked at 180 ° C. for 25 minutes.
サプリメント(錠剤)(実施例271〜280、比較例13)
表40〜41のAI成分とAJ成分を良く混ぜ合わせたものを、打錠機を用いてタブレット状に押し固め、錠剤(0.3g)を形成した。
Supplement (Tablet) (Examples 271 to 280, Comparative Example 13)
The well-mixed AI component and AJ component in Tables 40 to 41 were pressed into a tablet using a tableting machine to form tablets (0.3 g).
評 価
前記実施例261〜280、比較例12及び13の飲食物について、それぞれ女性2名ずつの(11群×2処方)計44名に対して、パンについては、毎日の朝食時に、前記実施例又は比較例のパンを主食として約90g摂取する、サプリメント(錠剤)については、毎日3回の食事後にサプリメント(錠剤)を5錠(1.5g)摂取する以外は通常の生活をして1ヶ月間続けるモニター試験を行い、その使用感を調べた。
下記の基準にて評価を行った結果を表42に示す。なお、使用期間中に皮膚の異常を訴えたものはいなかった。
有 効 :肌のハリ・ツヤ・弾力が増した
やや有効:肌のハリ・ツヤ・弾力がやや増した
効果無し:使用前と変化無し
Evaluation Regarding the foods and drinks of Examples 261 to 280 and Comparative Examples 12 and 13, a total of 44 women each (11 groups × 2 prescriptions), with regard to bread, at the time of daily breakfast For supplements (tablets) in which about 90 g of the bread of the example or comparative example is consumed as a staple food, a normal life is taken except for taking 5 tablets (1.5 g) of supplements (tablets) after 3 meals daily. A monthly monitor test was conducted to examine the feeling of use.
Table 42 shows the results of evaluation based on the following criteria. None of the patients complained of skin abnormalities during the period of use.
Effective: Skin elasticity, gloss, elasticity increased slightly Effective: Skin elasticity, gloss, elasticity increased slightly No effect: No change from before use
本発明の線維芽細胞増殖促進剤を配合した実施例261〜280の飲食物を摂取したモニターでは、肌のハリ・ツヤ・弾力が増すか又はやや増すとの評価結果であり、線維芽細胞増殖促進効果による老化現象の改善が認められた。一方、比較例12又は13の飲食物を摂取したモニターでは、肌のハリ・ツヤ・弾力は使用前と変化無しとの評価であったことから、本発明の飲食物の効果はいずれも有意であった。 In the monitor which ingested the food and drink of Examples 261-280 which mix | blended the fibroblast proliferation promoter of this invention, it is an evaluation result that the firmness, luster, elasticity of skin increases or slightly increases, and fibroblast proliferation The aging phenomenon was improved by the promoting effect. On the other hand, in the monitor which ingested the food / beverage of the comparative example 12 or 13, since the elasticity, luster, and elasticity of skin were evaluation before use and a change, all the effects of the food / beverage of this invention are significant. there were.
イトヒメハギエキス、クララエキス、シャクヤクエキス、カキエキス、タンジンエキス、ツボクサエキス、プーアルエキス、アルブチン、アスコルビン酸又はアルギン酸オリゴ糖類は線維芽細胞の増殖を促進するために、線維芽細胞において産生されるコラーゲン及びヒアルロン酸の量が相対的に増大し、その結果として、シワ、タルミの予防、緩和、改善がなされるので、老化現象の防止、改善を目的とした化粧品をはじめとする各種の皮膚外用剤、浴用剤、飲食物などへの利用が可能となる。 Cypress extract, Clara extract, Peonies extract, Oyster extract, Tanjin extract, Clover extract, Pual extract, Arbutin, Ascorbic acid or Alginate oligosaccharides are used to promote collagen growth in fibroblasts and The amount of hyaluronic acid is relatively increased, and as a result, wrinkles and tarmi are prevented, alleviated and improved, so various external preparations for skin including cosmetics aimed at preventing and improving the aging phenomenon, It can be used for bath preparation, food and drink.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006289307A JP2008105983A (en) | 2006-10-25 | 2006-10-25 | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006289307A JP2008105983A (en) | 2006-10-25 | 2006-10-25 | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008105983A true JP2008105983A (en) | 2008-05-08 |
Family
ID=39439638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006289307A Pending JP2008105983A (en) | 2006-10-25 | 2006-10-25 | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2008105983A (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008105985A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Hyaluronic acid production promoter, skin care preparation for external use, bathing agent, and food and drink |
JP2009051804A (en) * | 2007-08-02 | 2009-03-12 | Sanei Kagaku Kk | Hair cosmetic comprising alginate oligosaccharide (salt) |
JP2009114082A (en) * | 2007-11-02 | 2009-05-28 | Maruzen Pharmaceut Co Ltd | Hair papilla cell proliferation promoter, fibroblast growth factor-7 (fgf-7) production promoter, vascular endothelial growth factor (vegf) production promoter, antiandrogenic agent, hair grower and hair cosmetic |
WO2011030859A1 (en) * | 2009-09-11 | 2011-03-17 | ロート製薬株式会社 | Skin-whitening composition |
FR2958164A1 (en) * | 2010-04-01 | 2011-10-07 | Silab Sa | Use of an active ingredient derived from calyx of Diospyros kaki with specified amount of phenolic content, as antistress and antiaging agent in a cosmetic composition |
JP2012006838A (en) * | 2010-06-22 | 2012-01-12 | Sansho Seiyaku Co Ltd | External preparation for skin |
JP2013056866A (en) * | 2011-09-09 | 2013-03-28 | Pias Arise Kk | EXPRESSION ACTIVATING AGENT OF Bmal1 GENE AND METHOD FOR ACTIVATING EXPRESSION OF Bmal1 GENE |
JP2015529679A (en) * | 2012-09-14 | 2015-10-08 | イーエルシー マネージメント エルエルシー | Methods and compositions for improving selective degradation metabolism in keratin surface cells |
KR101700903B1 (en) * | 2016-06-03 | 2017-02-01 | 신형석 | Anti-wrinkle cosmetic composition containing centella asiatica extract, timosaponin, hyaluronic acid, collagen |
JP2017088525A (en) * | 2015-11-06 | 2017-05-25 | 株式会社ドクターズチョイス | Hyaluronic acid production promoter |
US10383815B2 (en) | 2012-09-14 | 2019-08-20 | Elc Management Llc | Method and compositions for improving selective catabolysis in cells of keratin surfaces |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
WO2021182873A1 (en) * | 2020-03-13 | 2021-09-16 | Medihelpline Co., Ltd. | A topical composition comprising an extract of combined herbs comprising longanae arillus for the skin regeneration and the treatment or alleviation of skin wound and the use thereof. |
KR20210116235A (en) * | 2020-03-13 | 2021-09-27 | 박옥남 | topical composition comprising the extract of combined herbs comprising Longanae Arillus for the treatment or alleviation of skin scar |
CN114010563A (en) * | 2021-11-30 | 2022-02-08 | 上海宜侬生物科技有限公司 | Component with brightening and anti-aging effects and application thereof |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61271210A (en) * | 1985-05-28 | 1986-12-01 | Pola Chem Ind Inc | Cosmetic |
JPH02290805A (en) * | 1989-04-28 | 1990-11-30 | Pias Arise Kk | Cosmetic for prevention of dermal senescence and its production |
JPH0366623A (en) * | 1989-08-03 | 1991-03-22 | Toreede Uindo Kk | Inhibitor of obesity and production thereof |
JPH03240736A (en) * | 1990-02-16 | 1991-10-28 | Ichimaru Pharcos Co Ltd | Cell activating substance derived from sophora angustifolia sieb. et zucc. |
JPH07238027A (en) * | 1994-02-25 | 1995-09-12 | Pola Chem Ind Inc | Arterioscelerosis inhibitor and food or medicine containing the same |
JPH0881378A (en) * | 1994-07-14 | 1996-03-26 | Maruha Corp | Human epidermal keratinized cell activator |
JPH08133948A (en) * | 1994-11-07 | 1996-05-28 | Shiseido Co Ltd | Skin preparation for external use |
JPH09163960A (en) * | 1995-12-15 | 1997-06-24 | Ariie Tomita | Health beverage and food or medicine containing the same beverage as active ingredient |
JPH11236334A (en) * | 1997-12-01 | 1999-08-31 | Nissin Food Prod Co Ltd | Cell adhesion inhibitor |
JP2000302634A (en) * | 1999-04-27 | 2000-10-31 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
JP2001048722A (en) * | 1999-07-02 | 2001-02-20 | L'oreal Sa | Skin-farming cosmetic composition containing at least one of hydroxystilbene in combination with ascorbic acid |
JP2001335500A (en) * | 2000-05-30 | 2001-12-04 | Taisho Pharmaceut Co Ltd | Refreshment promoter |
JP2002145788A (en) * | 2000-11-10 | 2002-05-22 | Pigeon Corp | Striae gravidarum formation inhibitor |
JP2002272420A (en) * | 2001-03-19 | 2002-09-24 | Maruha Corp | Antihypertension-relating ingestive material |
JP2002541074A (en) * | 1999-03-24 | 2002-12-03 | ラ・ロッシュ・ポセイ・ラボラトワール・ファーマスティーク | Use of vitamin C analogs for increasing the level of skin cell differentiation and / or proliferation |
JP2002363057A (en) * | 2001-06-08 | 2002-12-18 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor or cosmetic composition |
JP2003277261A (en) * | 2002-03-19 | 2003-10-02 | Dhc Co | Skin care preparation |
JP2003292432A (en) * | 2002-04-04 | 2003-10-15 | Noevir Co Ltd | Skin care preparation |
JP2003313117A (en) * | 2002-04-22 | 2003-11-06 | Nicca Chemical Co Ltd | Lipase activity activator, skin care preparation containing the lipase activity activator and used for slimming body, and bathing agent containing the lipase activity activator and used for slimming body |
JP2003342181A (en) * | 2002-05-28 | 2003-12-03 | Noevir Co Ltd | Skin external preparation |
JP2004002433A (en) * | 2003-06-02 | 2004-01-08 | Pola Chem Ind Inc | Skin external preparation for alpha-msh suppression |
JP2004059482A (en) * | 2002-07-29 | 2004-02-26 | Masahiro Sakanaka | Tissue regeneration promoter |
JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
JP2004284999A (en) * | 2003-03-24 | 2004-10-14 | Kose Corp | Skin disorder inhibitor, skin disorder ameliorant and external preparation for skin containing the same |
JP2004305089A (en) * | 2003-04-07 | 2004-11-04 | Taisho Pharmaceut Co Ltd | Drink composition |
JP2005239659A (en) * | 2004-02-27 | 2005-09-08 | Nicca Chemical Co Ltd | Precursor lipocyte differentiation inhibitor |
JP2005239660A (en) * | 2004-02-27 | 2005-09-08 | Nicca Chemical Co Ltd | Precursor lipocyte differentiation promoter |
JP2005278478A (en) * | 2004-03-29 | 2005-10-13 | Asahi Soft Drinks Co Ltd | Rebound preventing beverage and fat absorption restraining agent each containing post-heating fermented tea |
JP2006063067A (en) * | 2004-07-30 | 2006-03-09 | Ezaki Glico Co Ltd | Skin care preparation for external use |
JP2006508905A (en) * | 2002-07-08 | 2006-03-16 | ラボラトイレス クラリンス | Cosmetic composition capable of combating skin aging |
JP2006117612A (en) * | 2004-10-25 | 2006-05-11 | Ichimaru Pharcos Co Ltd | Active oxygen eliminating agent |
JP2006160629A (en) * | 2004-12-03 | 2006-06-22 | Naris Cosmetics Co Ltd | Collagen production accelerator and external preparation for skin containing the same |
JP2006320320A (en) * | 2005-04-22 | 2006-11-30 | Meiji Univ | High-temperature extract composition of marine alga, heat-treated composition of marine alga, method for producing them and seasoning, cosmetic, food and health food containing high-temperature extract composition of marine alga or heat-treated composition of marine alga |
JP2007204449A (en) * | 2006-02-03 | 2007-08-16 | Pias Arise Kk | Production inhibitor of matrix metalloprotease-9 and endothelin-1, and agent for preventing or ameliorating pigmentation after inflammation, and cosmetic, containing the production inhibitor formulated therewith |
JP2007246410A (en) * | 2006-03-14 | 2007-09-27 | Mandom Corp | Sun burn cell formation inhibitor and dna damage repair promoter |
JP2008024703A (en) * | 2006-06-23 | 2008-02-07 | Rohto Pharmaceut Co Ltd | Composition having collagen production-promoting ability and/or fibroblast proliferation-promoting ability |
JP2008105985A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Hyaluronic acid production promoter, skin care preparation for external use, bathing agent, and food and drink |
JP2008105984A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Collagen production promoter, skin care preparation for external use, bathing agent, and food and drink |
-
2006
- 2006-10-25 JP JP2006289307A patent/JP2008105983A/en active Pending
Patent Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61271210A (en) * | 1985-05-28 | 1986-12-01 | Pola Chem Ind Inc | Cosmetic |
JPH02290805A (en) * | 1989-04-28 | 1990-11-30 | Pias Arise Kk | Cosmetic for prevention of dermal senescence and its production |
JPH0366623A (en) * | 1989-08-03 | 1991-03-22 | Toreede Uindo Kk | Inhibitor of obesity and production thereof |
JPH03240736A (en) * | 1990-02-16 | 1991-10-28 | Ichimaru Pharcos Co Ltd | Cell activating substance derived from sophora angustifolia sieb. et zucc. |
JPH07238027A (en) * | 1994-02-25 | 1995-09-12 | Pola Chem Ind Inc | Arterioscelerosis inhibitor and food or medicine containing the same |
JPH0881378A (en) * | 1994-07-14 | 1996-03-26 | Maruha Corp | Human epidermal keratinized cell activator |
JPH08133948A (en) * | 1994-11-07 | 1996-05-28 | Shiseido Co Ltd | Skin preparation for external use |
JPH09163960A (en) * | 1995-12-15 | 1997-06-24 | Ariie Tomita | Health beverage and food or medicine containing the same beverage as active ingredient |
JPH11236334A (en) * | 1997-12-01 | 1999-08-31 | Nissin Food Prod Co Ltd | Cell adhesion inhibitor |
JP2002541074A (en) * | 1999-03-24 | 2002-12-03 | ラ・ロッシュ・ポセイ・ラボラトワール・ファーマスティーク | Use of vitamin C analogs for increasing the level of skin cell differentiation and / or proliferation |
JP2000302634A (en) * | 1999-04-27 | 2000-10-31 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
JP2001048722A (en) * | 1999-07-02 | 2001-02-20 | L'oreal Sa | Skin-farming cosmetic composition containing at least one of hydroxystilbene in combination with ascorbic acid |
JP2001335500A (en) * | 2000-05-30 | 2001-12-04 | Taisho Pharmaceut Co Ltd | Refreshment promoter |
JP2002145788A (en) * | 2000-11-10 | 2002-05-22 | Pigeon Corp | Striae gravidarum formation inhibitor |
JP2002272420A (en) * | 2001-03-19 | 2002-09-24 | Maruha Corp | Antihypertension-relating ingestive material |
JP2002363057A (en) * | 2001-06-08 | 2002-12-18 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor or cosmetic composition |
JP2003277261A (en) * | 2002-03-19 | 2003-10-02 | Dhc Co | Skin care preparation |
JP2003292432A (en) * | 2002-04-04 | 2003-10-15 | Noevir Co Ltd | Skin care preparation |
JP2003313117A (en) * | 2002-04-22 | 2003-11-06 | Nicca Chemical Co Ltd | Lipase activity activator, skin care preparation containing the lipase activity activator and used for slimming body, and bathing agent containing the lipase activity activator and used for slimming body |
JP2003342181A (en) * | 2002-05-28 | 2003-12-03 | Noevir Co Ltd | Skin external preparation |
JP2006508905A (en) * | 2002-07-08 | 2006-03-16 | ラボラトイレス クラリンス | Cosmetic composition capable of combating skin aging |
JP2004059482A (en) * | 2002-07-29 | 2004-02-26 | Masahiro Sakanaka | Tissue regeneration promoter |
JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
JP2004284999A (en) * | 2003-03-24 | 2004-10-14 | Kose Corp | Skin disorder inhibitor, skin disorder ameliorant and external preparation for skin containing the same |
JP2004305089A (en) * | 2003-04-07 | 2004-11-04 | Taisho Pharmaceut Co Ltd | Drink composition |
JP2004002433A (en) * | 2003-06-02 | 2004-01-08 | Pola Chem Ind Inc | Skin external preparation for alpha-msh suppression |
JP2005239659A (en) * | 2004-02-27 | 2005-09-08 | Nicca Chemical Co Ltd | Precursor lipocyte differentiation inhibitor |
JP2005239660A (en) * | 2004-02-27 | 2005-09-08 | Nicca Chemical Co Ltd | Precursor lipocyte differentiation promoter |
JP2005278478A (en) * | 2004-03-29 | 2005-10-13 | Asahi Soft Drinks Co Ltd | Rebound preventing beverage and fat absorption restraining agent each containing post-heating fermented tea |
JP2006063067A (en) * | 2004-07-30 | 2006-03-09 | Ezaki Glico Co Ltd | Skin care preparation for external use |
JP2006117612A (en) * | 2004-10-25 | 2006-05-11 | Ichimaru Pharcos Co Ltd | Active oxygen eliminating agent |
JP2006160629A (en) * | 2004-12-03 | 2006-06-22 | Naris Cosmetics Co Ltd | Collagen production accelerator and external preparation for skin containing the same |
JP2006320320A (en) * | 2005-04-22 | 2006-11-30 | Meiji Univ | High-temperature extract composition of marine alga, heat-treated composition of marine alga, method for producing them and seasoning, cosmetic, food and health food containing high-temperature extract composition of marine alga or heat-treated composition of marine alga |
JP2007204449A (en) * | 2006-02-03 | 2007-08-16 | Pias Arise Kk | Production inhibitor of matrix metalloprotease-9 and endothelin-1, and agent for preventing or ameliorating pigmentation after inflammation, and cosmetic, containing the production inhibitor formulated therewith |
JP2007246410A (en) * | 2006-03-14 | 2007-09-27 | Mandom Corp | Sun burn cell formation inhibitor and dna damage repair promoter |
JP2008024703A (en) * | 2006-06-23 | 2008-02-07 | Rohto Pharmaceut Co Ltd | Composition having collagen production-promoting ability and/or fibroblast proliferation-promoting ability |
JP2008105985A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Hyaluronic acid production promoter, skin care preparation for external use, bathing agent, and food and drink |
JP2008105984A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Collagen production promoter, skin care preparation for external use, bathing agent, and food and drink |
Non-Patent Citations (7)
Title |
---|
JPN6012045225; 香栄興業株式会社 植物エキス製品カタログ 第1版, 20050912, p54, 香栄興業株式会社 * |
JPN6012045227; 原色牧野和漢薬草第図鑑 2版, 19980730, p229, 株式会社北隆館 * |
JPN6012045228; Fragrance Journal Vol.32,No.12, 200412, p51-55 * |
JPN6012045229; Fragrance Journal 臨時増刊 No.9, 1988, p182,188 * |
JPN6012045230; 健康・栄養食品研究 Vol.5,No.3, 2002, p41-54 * |
JPN6014036645; 蔵多淑子ら編、化粧品ハンドブック、日光ケミカルズ株式会社、平成8年11月1日発行、455-457頁 , 1996 |
JPN7014002572; STN ON THE WEB, CAPLUS FILE, ABSTRACT NO. 1999:620117 , 1999 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008105985A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Hyaluronic acid production promoter, skin care preparation for external use, bathing agent, and food and drink |
JP2009051804A (en) * | 2007-08-02 | 2009-03-12 | Sanei Kagaku Kk | Hair cosmetic comprising alginate oligosaccharide (salt) |
JP2009114082A (en) * | 2007-11-02 | 2009-05-28 | Maruzen Pharmaceut Co Ltd | Hair papilla cell proliferation promoter, fibroblast growth factor-7 (fgf-7) production promoter, vascular endothelial growth factor (vegf) production promoter, antiandrogenic agent, hair grower and hair cosmetic |
WO2011030859A1 (en) * | 2009-09-11 | 2011-03-17 | ロート製薬株式会社 | Skin-whitening composition |
FR2958164A1 (en) * | 2010-04-01 | 2011-10-07 | Silab Sa | Use of an active ingredient derived from calyx of Diospyros kaki with specified amount of phenolic content, as antistress and antiaging agent in a cosmetic composition |
JP2012006838A (en) * | 2010-06-22 | 2012-01-12 | Sansho Seiyaku Co Ltd | External preparation for skin |
JP2013056866A (en) * | 2011-09-09 | 2013-03-28 | Pias Arise Kk | EXPRESSION ACTIVATING AGENT OF Bmal1 GENE AND METHOD FOR ACTIVATING EXPRESSION OF Bmal1 GENE |
US10383815B2 (en) | 2012-09-14 | 2019-08-20 | Elc Management Llc | Method and compositions for improving selective catabolysis in cells of keratin surfaces |
JP2015529679A (en) * | 2012-09-14 | 2015-10-08 | イーエルシー マネージメント エルエルシー | Methods and compositions for improving selective degradation metabolism in keratin surface cells |
CN104797237B (en) * | 2012-09-14 | 2020-11-24 | Elc 管理有限责任公司 | Methods and compositions for improving selective catabolism in cells on the surface of keratin |
JP2017088525A (en) * | 2015-11-06 | 2017-05-25 | 株式会社ドクターズチョイス | Hyaluronic acid production promoter |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11998575B2 (en) | 2016-03-31 | 2024-06-04 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11633451B2 (en) | 2016-03-31 | 2023-04-25 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
KR101700903B1 (en) * | 2016-06-03 | 2017-02-01 | 신형석 | Anti-wrinkle cosmetic composition containing centella asiatica extract, timosaponin, hyaluronic acid, collagen |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
WO2021182873A1 (en) * | 2020-03-13 | 2021-09-16 | Medihelpline Co., Ltd. | A topical composition comprising an extract of combined herbs comprising longanae arillus for the skin regeneration and the treatment or alleviation of skin wound and the use thereof. |
CN115297879A (en) * | 2020-03-13 | 2022-11-04 | (株)美迪合伙来音 | Topical composition comprising arillus longan combined crude drug extract for regenerating skin and treating or improving skin wound, and its application |
KR102374383B1 (en) * | 2020-03-13 | 2022-03-15 | 박옥남 | topical composition comprising the extract of combined herbs comprising Longanae Arillus for skin regeneration and the treatment or alleviation of skin scar |
JP2023518224A (en) * | 2020-03-13 | 2023-04-28 | メディヘルプライン カンパニー,リミテッド | Topical composition containing longan meat-containing mixed herbal extract and its use for skin regeneration and treatment or amelioration of skin wounds |
KR20210116235A (en) * | 2020-03-13 | 2021-09-27 | 박옥남 | topical composition comprising the extract of combined herbs comprising Longanae Arillus for the treatment or alleviation of skin scar |
CN114010563A (en) * | 2021-11-30 | 2022-02-08 | 上海宜侬生物科技有限公司 | Component with brightening and anti-aging effects and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008105983A (en) | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink | |
JP2008105985A (en) | Hyaluronic acid production promoter, skin care preparation for external use, bathing agent, and food and drink | |
JP5913118B2 (en) | Collagen production promoter, hyaluronic acid production promoter, fibroblast proliferation promoter, and anti-wrinkle agent | |
KR20100135871A (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
KR101319990B1 (en) | Cosmetic composition comprising an asparagus cochinchinensis and maca complex-fermented extract | |
JP4425163B2 (en) | Anti-aging cosmetics | |
JP2008105984A (en) | Collagen production promoter, skin care preparation for external use, bathing agent, and food and drink | |
JP2008088075A (en) | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method | |
JP5014343B2 (en) | Nemagaridake-containing composition, moisturizer, cell activator, whitening agent and antioxidant | |
JPH1029924A (en) | Antiaging agent | |
JP2011195537A (en) | Antioxidant, whitening agent, anti-aging agent, hair tonic, humectant, skin care preparation and functional oral composition | |
JP2010070501A (en) | Moisturizer, anti-aging agent, antioxidant, neutral fat-accumulation inhibitor, skin-beautifying agent, antiinflammatory agent, skin preparation for external use and peroral preparation | |
JP5711879B2 (en) | Fibroblast growth factor-7 production promoter, scalp / hair cosmetic containing the same, and food and drink | |
JP5062980B2 (en) | Moisturizer, collagen production promoter, whitening agent, antioxidant, and vascular endothelial growth factor production promoter | |
JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
KR100983076B1 (en) | Skin cream cosmetic composition | |
JP2021187787A (en) | Exosome secretagogue, exosome uptake promoter, exosome secretion-promoting beauty composition, and exosome secretion promoting method | |
JP5932948B2 (en) | Fibroblast growth factor-7 production promoter, scalp / hair cosmetic containing the same, and food and drink | |
JP5171752B2 (en) | Topical skin preparation | |
JP5247548B2 (en) | Moisturizer, anti-aging agent, neutral fat accumulation inhibitor, whitening agent, anti-inflammatory agent, topical skin preparation, oral preparation | |
JP2004182710A (en) | Collagen production-accelerating agent | |
JP2011168560A (en) | Anti-aging agent, antioxidant, whitening agent, immunoactivator, skin care preparation and functional oral composition | |
JP4480366B2 (en) | Cell activator, whitening agent, hyaluronic acid production promoter, collagen production promoter, antioxidant, and skin external preparation | |
JP5202180B2 (en) | Moisturizer, immunostimulant, anti-aging agent, whitening agent, antioxidant, slimming agent, external preparation for skin and functional oral composition | |
JP2004217578A (en) | Cell activator, antioxidant, and skin care preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090807 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110906 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120904 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121029 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121127 |